[HTML][HTML] Critical role of IL-10 in the induction of low zone tolerance to contact allergens

M Maurer, W Seidel-Guyenot, M Metz… - The Journal of …, 2003 - Am Soc Clin Investig
M Maurer, W Seidel-Guyenot, M Metz, J Knop, K Steinbrink
The Journal of clinical investigation, 2003Am Soc Clin Investig
The development and mechanisms of tolerance to allergens are poorly understood. Using
the murine low zone tolerance (LZT) model, where contact hypersensitivity (CHS) is
prevented by repeated topical low-dose applications of contact allergens, we show that LZT
induction is IL-10 dependent. IL-10 is required for the generation of LZT effector cells, that is,
CD8+ regulatory T cells. Only T cells from tolerized IL-10+/+ mice or IL-10–/–mice
reconstituted with IL-10 during LZT induction adoptively transferred LZT to naive mice and …
The development and mechanisms of tolerance to allergens are poorly understood. Using the murine low zone tolerance (LZT) model, where contact hypersensitivity (CHS) is prevented by repeated topical low-dose applications of contact allergens, we show that LZT induction is IL-10 dependent. IL-10 is required for the generation of LZT effector cells, that is, CD8+ regulatory T cells. Only T cells from tolerized IL-10+/+ mice or IL-10–/–mice reconstituted with IL-10 during LZT induction adoptively transferred LZT to naive mice and prevented CHS, whereas T cells from IL-10–/–mice failed to do so. The IL-10 required for normal LZT development is derived from lymph node CD4+ T cells, the only skin or lymph node cell population found to produce relevant amounts of IL-10 after tolerization. CD4+ T cells derived from IL-10+/+ mice, but not from IL-10–/–mice, allowed the induction of LZT in adoptively transferred T cell–deficient mice. Interestingly, IL-10 injections during tolerization greatly enhanced LZT responses in normal mice. Thus, the generation of CD8+ LZT effector T cells by CD4+ regulatory T cells via IL-10 may be a promising target of strategies aimed at preventing contact allergies and other harmful immune responses.
The Journal of Clinical Investigation